Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
P/E ratio for Xenon Pharmaceuticals Inc. (XENE)
P/E ratio as of 2023: -16.89
According to Xenon Pharmaceuticals Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -16.89. At the end of 2022 the company had a P/E ratio of -19.04.
P/E ratio history for Xenon Pharmaceuticals Inc. from 2011 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -16.89 |
| 2022 | -19.04 |
| 2021 | -17.28 |
| 2020 | -18.42 |
| 2019 | -8.18 |
| 2018 | -3.55 |
| 2017 | -1.66 |
| 2016 | -5.19 |
| 2015 | -7.29 |
| 2014 | 4.80 |
| 2013 | 7.93 |
| 2012 | -22.18 |
| 2011 | -7.95 |